Physiological platelet receptors and hemostatic ligands

Physiological platelet receptors and hemostatic ligands represent a collective group of molecules essential for blood clot formation and vascular integrity (StatPearls, 2023). This group includes surface receptors such as the P2Y12 purinergic receptor, the Glycoprotein Ib-IX-V complex, and the integrin Glycoprotein IIb/IIIa, which respond to ligands like adenosine diphosphate (ADP), von Willebrand factor (vWF), and fibrinogen (PubMed, 2017). These interactions facilitate the initial adhesion of platelets to damaged endothelium, followed by activation and the recruitment of additional platelets to form a stable aggregate (Journal of Thrombosis and Haemostasis, 2018). While vital for preventing blood loss, overactivity of these pathways is a primary driver of arterial thrombosis, contributing to life-threatening events such as myocardial infarction and stroke (NIH, 2022). Consequently, these receptors are the focus of numerous pharmacological interventions, including P2Y12 inhibitors and GPIIb/IIIa antagonists, which are standard of care in managing acute coronary syndromes (Circulation, 2019). Balancing the efficacy of these drugs in preventing thrombosis against the risk of clinical bleeding remains a significant therapeutic challenge.

Other names

Platelet surface receptorsHemostatic signaling moleculesPlatelet glycoproteins and ligandsPlatelet activation receptors

Inhibition of platelet activation and aggregation through various pathways, including P2Y12 purinergic receptor antagonism, Glycoprotein IIb/IIIa receptor blockade, and Protease-activated receptor-1 (PAR-1) antagonism.